TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Oct 25, 2021 19:00 JST
Source:
Genetec Technology Bhd
Genetec Q2FY2022 PAT Up by Sixfold
Company records strong Q2 performance of RM16.30 million, exceeding industry expectations
BANGI, Malaysia, Oct 25, 2021 - (ACN Newswire) - Genetec Technology Berhad ("Genetec" or the "Company"), a technology leader in providing customised full turnkey smart factory automation manufacturing lines, today announced that the Company recorded profit after tax ("PAT") of RM16.30 million for the second quarter ended 30 September 2021 ("Q2FY2022"), which is 515% higher than the PAT of RM2.65 million registered for the corresponding second quarter ended 30 September 2020 ("Q2FY2021").
Genetec also announced their proposal of a bonus issue of 661,564,800 new ordinary shares in Genetec ("Bonus Shares") on the basis of twelve (12) Bonus Shares for every one (1) existing ordinary share in Genetec ("Genetec Share" or "Share") held on an entitlement date to be determined later ("Proposed Bonus Issue"). The Entitlement Date will be determined and announced at a later date upon receipt of all relevant approvals for the Proposed Bonus Issue. In addition, for purposes of clarity, the actual number of Bonus Shares to be issued will depend on the total number of issued Shares on the Entitlement Date and is not intended to be implemented on a staggered basis. Further and final details will be announced upon receipt of all relevant approvals soon.
Genetec registered RM17.59 million in profit before tax ("PBT") for the quarter under review, which is 554% higher than the PBT of RM2.69 million recorded for Q2FY2021 while revenue of RM59.31 million is 53% higher than the RM38.67 million posted in Q2FY2021. Earnings per share stood at 31.25 sen (fully diluted) in Q2FY2022 compared to EPS of 6.18 sen in Q2FY2021.
For the first-half of the financial year ended 31 March 2022 ("1HFY2022"), the Company recorded 2884% higher PAT of RM24.50 million compared to the corresponding period of the previous financial year, when the Company posted PAT of RM821,000. PBT for 1HFY2022 stood at RM26.44 million, which is 2848% higher than the PBT of RM897,000 while revenue is 95% higher at RM99.59 million compared to RM51.10 million of the corresponding period of the previous financial year.
In their announcements the Company highlighted, "It has been an eventful year. Genetec's bonus issue proposal is part of our efforts to enhance trading liquidity of the Genetec shares, following the recent share price appreciation, as well as to reward existing shareholders on the back of the strong performance of the EV and energy storage divisions. The strong performances have contributed significantly to overall revenue amid steady demand for more sustainable modes of transport and energy. We expect the order book for the EV division to remain significant and to continue contributing to Genetec's financial performance in the coming quarters. As countries and companies step up their transition towards more sustainable and zero emission transport and energy solutions, we are confident that this growth trajectory will continue. It is well supported by the trifecta of global regulatory frameworks, new incentives to promote the adoption of EVs, and a fast-expanding range of EVs. Meanwhile, EV models are becoming more accessible as the ecosystem grows and battery costs drop further."
"While we have a more positive outlook as the global economy reopens amid higher vaccination rates, we remain cautious of spikes in COVID-19 infections that may result in supply-chain disruptions and affect consumer sentiment."
Source: Genetec Technology Bhd
Sectors: Daily Finance, Local Biz, Manufacturing
Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Genetec reinforces foundation for growth, maintains resilient outlook
August 30 2025 23:59 JST
Genetec maintains profitability in Q3FY2025 on higher revenue
May 29 2025 20:00 JST
Genetec maintains stable and profitable performance on a lower Q1FY2025 revenue
November 27 2024 10:00 JST
Genetec's Consistent Performance Delivers Higher Overall Margins in Q4FY2024
May 28 2024 19:18 JST
Genetec Sets the Stage for Higher Growth Following a Strong Q3FY2024 Performance
February 27 2024 20:00 JST
Genetec Powers ahead with Steady Growth in Q2FY2024
November 29 2023 17:00 JST
Genetec's Q2FY2023 Performance Remains on Track
November 29 2022 17:00 JST
Genetec's Quarterly Performance Jumps by 126%
August 29 2022 18:00 JST
Genetec Scales New Heights with Highest Annual Profit to Date
May 26 2022 18:00 JST
Genetec Delivers Its Best Quarter to Date
January 26 2022 16:00 JST
More Press release >>
Latest Press Release
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Jul 18, 2026 00:24 JST
Hitachi and NVIDIA collaborate to advance HMAX and enable end-to-end autonomous operations through the integrated control of physical AI
Jul 17, 2026 23:35 JST
Toyota's First "BE creation" Spin-Off Begins Operations in Japan
Jul 17, 2026 23:00 JST
MHI Advances AI Infrastructure Commercialization with U.S. Deployment of 10MW-Class Chiller and MCP Development
Jul 17, 2026 22:47 JST
Noetra Launches Full-Scale R&D for Japan-Developed Multimodal Foundation Model
Jul 17, 2026 22:16 JST
Mitsubishi Motors Launches the Xforce HEV in Indonesia
Jul 17, 2026 21:47 JST
Fujitsu to explore physical AI development and implementation across industries with FANUC, Yaskawa Electric, and Kawasaki Heavy Industries integrating NVIDIA technology
Jul 17, 2026 21:05 JST
JCB Celebrates 30 Years of Trust, Honoring 70 Years of Japan-Philippines Friendship
Jul 17, 2026 10:00 JST
TANAKA Commences Operation of "TANAKA H2 Nexus", One of Japan's Largest 500 kW Pure Hydrogen Fuel Cell Power Generation Facilities
Jul 16, 2026 22:00 JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Jul 16, 2026 00:18 JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 23:51 JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 15, 2026 23:21 JST
NEC develops world's first proprietary-AI technology to rapidly generate highly detailed 3D models solely from general-purpose camera footage while automatically removing unnecessary subjects
Jul 15, 2026 22:53 JST
Hitachi Rail achieves EcoVadis platinum medal, ranking among the top 1% of companies worldwide for sustainability performance
Jul 15, 2026 22:35 JST
Anime Tokyo Station Reaches 300,000 Visitors!
Jul 15, 2026 11:00 JST
Fujitsu launches AI-driven modernization service to accelerate legacy system transformation
Jul 14, 2026 19:12 JST
Anime Tokyo Station: TV Anime "BLEACH: THE BLOOD WARFARE - The Calamity" Special Exhibition
Jul 14, 2026 11:00 JST
JCB Signs Memorandum of Understanding with Circle to Explore Collaboration Utilizing Stablecoins
Jul 14, 2026 10:00 JST
Mitsubishi Power Receives Contract to Supply Boilers for Fuel Conversion Work at Existing Thermal Power Plants in Saudi Arabia
Jul 14, 2026 00:58 JST
Fujitsu developed an AI Agent to collaborate with store managers for AEON Food Style's strategic store operations
Jul 14, 2026 00:38 JST
More Latest Release >>